Jaguar Health, Inc. (NASDAQ: JAGX)

Jaguar Health, Inc., a commercial-stage pharmaceutical company, operates within the healthcare industry, specifically focusing on developing novel, proprietary prescription medicines derived from plants for people and animals with gastrointestinal distress (Jaguar Health, Inc.). The company's primary business activities include the development and commercialization of human prescription pharmaceuticals for essential supportive care and managing neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar Health's operations span various countries, with its main segments being Human Health, Animal Health, and Magdalena Biosciences.

The company generates revenue through the sale of its primary products, including Mytesi, a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, and Canalevia-CA, a first-in-class oral plant-based prescription product conditionally approved by the FDA for the treatment of chemotherapy-induced diarrhea in dogs. Jaguar Health holds a leading position within the industry, distinguished by its proprietary library of 2,300 highly characterized medicinal plants and 3,500 plant extracts, its expertise in ethnobotanical research, and its ability to develop novel, first-in-class prescription medicines. Key competitors include other pharmaceutical companies developing proprietary prescription medicines for gastrointestinal distress, such as Pfizer, GSK, and Novartis.

Jaguar Health's Human Health segment is dedicated to the development and commercialization of Mytesi, which is the only oral plant-based botanical prescription medicine approved under the FDA's Botanical Guidance. This approval provides an entry barrier from potential generic competition, allowing Mytesi to be marketed and distributed through a network of pharmaceutical companies, wholesalers, and retailers.

The Animal Health segment focuses on the development and commercialization of Canalevia-CA, conditionally approved by the FDA for the treatment of chemotherapy-induced diarrhea in dogs. Additionally, the company is developing products for dairy calves and foals.

In collaboration with Filament Health Corp., Jaguar has formed Magdalena Biosciences, a joint venture dedicated to developing novel, natural prescription medicines derived from plants for mental health indications, including attention-deficit/hyperactivity disorder (ADHD) in adults.

Jaguar's customer base includes patients with HIV/AIDS, cancer patients undergoing chemotherapy, and patients with inflammatory bowel disease. The company's products are marketed and distributed through a network of pharmaceutical companies, wholesalers, and retailers.